Logo image of TBPH

THERAVANCE BIOPHARMA INC (TBPH) Stock Fundamental Analysis

NASDAQ:TBPH - Nasdaq - KYG8807B1068 - Common Stock - Currency: USD

11.52  +0.31 (+2.77%)

After market: 11.52 0 (0%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to TBPH. TBPH was compared to 194 industry peers in the Pharmaceuticals industry. The financial health of TBPH is average, but there are quite some concerns on its profitability. TBPH is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

TBPH had negative earnings in the past year.
In the past year TBPH had a positive cash flow from operations.
TBPH had negative earnings in 4 of the past 5 years.
TBPH had a negative operating cash flow in each of the past 5 years.
TBPH Yearly Net Income VS EBIT VS OCF VS FCFTBPH Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M 600M 800M

1.2 Ratios

TBPH has a better Return On Assets (-16.98%) than 62.37% of its industry peers.
TBPH's Return On Equity of -35.14% is fine compared to the rest of the industry. TBPH outperforms 60.82% of its industry peers.
Industry RankSector Rank
ROA -16.98%
ROE -35.14%
ROIC N/A
ROA(3y)37.73%
ROA(5y)0.15%
ROE(3y)46.45%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
TBPH Yearly ROA, ROE, ROICTBPH Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 -200 400

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for TBPH so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
TBPH Yearly Profit, Operating, Gross MarginsTBPH Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1K -1K

More info and screens

6

2. Health

2.1 Basic Checks

TBPH does not have a ROIC to compare to the WACC, probably because it is not profitable.
TBPH has more shares outstanding than it did 1 year ago.
The number of shares outstanding for TBPH has been reduced compared to 5 years ago.
The debt/assets ratio for TBPH is higher compared to a year ago.
TBPH Yearly Shares OutstandingTBPH Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
TBPH Yearly Total Debt VS Total AssetsTBPH Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

Based on the Altman-Z score of -1.88, we must say that TBPH is in the distress zone and has some risk of bankruptcy.
TBPH's Altman-Z score of -1.88 is in line compared to the rest of the industry. TBPH outperforms 49.48% of its industry peers.
TBPH has a debt to FCF ratio of 0.96. This is a very positive value and a sign of high solvency as it would only need 0.96 years to pay back of all of its debts.
The Debt to FCF ratio of TBPH (0.96) is better than 96.39% of its industry peers.
A Debt/Equity ratio of 0.19 indicates that TBPH is not too dependend on debt financing.
TBPH has a Debt to Equity ratio (0.19) which is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.19
Debt/FCF 0.96
Altman-Z -1.88
ROIC/WACCN/A
WACC9.69%
TBPH Yearly LT Debt VS Equity VS FCFTBPH Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M

2.3 Liquidity

A Current Ratio of 4.77 indicates that TBPH has no problem at all paying its short term obligations.
With a decent Current ratio value of 4.77, TBPH is doing good in the industry, outperforming 69.07% of the companies in the same industry.
A Quick Ratio of 4.77 indicates that TBPH has no problem at all paying its short term obligations.
The Quick ratio of TBPH (4.77) is better than 70.62% of its industry peers.
Industry RankSector Rank
Current Ratio 4.77
Quick Ratio 4.77
TBPH Yearly Current Assets VS Current LiabilitesTBPH Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

More info and screens

4

3. Growth

3.1 Past

The earnings per share for TBPH have decreased strongly by -30.23% in the last year.
Looking at the last year, TBPH shows a small growth in Revenue. The Revenue has grown by 6.18% in the last year.
Measured over the past years, TBPH shows a decrease in Revenue. The Revenue has been decreasing by -2.59% on average per year.
EPS 1Y (TTM)-30.23%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-12.5%
Revenue 1Y (TTM)6.18%
Revenue growth 3Y5.2%
Revenue growth 5Y-2.59%
Sales Q2Q%6.1%

3.2 Future

TBPH is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 36.17% yearly.
Based on estimates for the next years, TBPH will show a very strong growth in Revenue. The Revenue will grow by 28.13% on average per year.
EPS Next Y135.84%
EPS Next 2Y24.79%
EPS Next 3Y27.11%
EPS Next 5Y36.17%
Revenue Next Year52.71%
Revenue Next 2Y22.83%
Revenue Next 3Y27.17%
Revenue Next 5Y28.13%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
TBPH Yearly Revenue VS EstimatesTBPH Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 100M 200M 300M
TBPH Yearly EPS VS EstimatesTBPH Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 5 -5 10

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

TBPH reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for TBPH. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TBPH Price Earnings VS Forward Price EarningsTBPH Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20 -20 30

4.2 Price Multiples

Based on the Price/Free Cash Flow ratio, TBPH is valued cheaply inside the industry as 84.54% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 17.84
EV/EBITDA N/A
TBPH Per share dataTBPH EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 3

4.3 Compensation for Growth

TBPH's earnings are expected to grow with 27.11% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y24.79%
EPS Next 3Y27.11%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for TBPH!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

THERAVANCE BIOPHARMA INC

NASDAQ:TBPH (8/8/2025, 8:08:26 PM)

After market: 11.52 0 (0%)

11.52

+0.31 (+2.77%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)05-08 2025-05-08/amc
Earnings (Next)08-12 2025-08-12/amc
Inst Owners91.75%
Inst Owner Change0.35%
Ins Owners4.71%
Ins Owner Change2.27%
Market Cap576.00M
Analysts80
Price Target17.54 (52.26%)
Short Float %8.28%
Short Ratio15.25
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-30.41%
Min EPS beat(2)-44.72%
Max EPS beat(2)-16.1%
EPS beat(4)0
Avg EPS beat(4)-26.03%
Min EPS beat(4)-44.72%
Max EPS beat(4)-10.35%
EPS beat(8)2
Avg EPS beat(8)-14.88%
EPS beat(12)3
Avg EPS beat(12)-28.11%
EPS beat(16)5
Avg EPS beat(16)-26.92%
Revenue beat(2)1
Avg Revenue beat(2)2.46%
Min Revenue beat(2)-2.67%
Max Revenue beat(2)7.58%
Revenue beat(4)2
Avg Revenue beat(4)0.79%
Min Revenue beat(4)-9.55%
Max Revenue beat(4)7.78%
Revenue beat(8)4
Avg Revenue beat(8)-0.96%
Revenue beat(12)5
Avg Revenue beat(12)-4.23%
Revenue beat(16)6
Avg Revenue beat(16)-5.07%
PT rev (1m)1.18%
PT rev (3m)12.79%
EPS NQ rev (1m)0%
EPS NQ rev (3m)373.58%
EPS NY rev (1m)0%
EPS NY rev (3m)214.67%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)61.7%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.43%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 8.83
P/FCF 17.84
P/OCF 17.71
P/B 3.47
P/tB 3.47
EV/EBITDA N/A
EPS(TTM)-1.12
EYN/A
EPS(NY)-0.48
Fwd EYN/A
FCF(TTM)0.65
FCFY5.61%
OCF(TTM)0.65
OCFY5.65%
SpS1.31
BVpS3.32
TBVpS3.32
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -16.98%
ROE -35.14%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM 49.47%
ROA(3y)37.73%
ROA(5y)0.15%
ROE(3y)46.45%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.19
Health
Industry RankSector Rank
Debt/Equity 0.19
Debt/FCF 0.96
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.77
Quick Ratio 4.77
Altman-Z -1.88
F-Score4
WACC9.69%
ROIC/WACCN/A
Cap/Depr(3y)20.39%
Cap/Depr(5y)43.25%
Cap/Sales(3y)1.99%
Cap/Sales(5y)4.27%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-30.23%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-12.5%
EPS Next Y135.84%
EPS Next 2Y24.79%
EPS Next 3Y27.11%
EPS Next 5Y36.17%
Revenue 1Y (TTM)6.18%
Revenue growth 3Y5.2%
Revenue growth 5Y-2.59%
Sales Q2Q%6.1%
Revenue Next Year52.71%
Revenue Next 2Y22.83%
Revenue Next 3Y27.17%
Revenue Next 5Y28.13%
EBIT growth 1Y-10.98%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y118.62%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y118.9%
OCF growth 3YN/A
OCF growth 5YN/A